Generic Name and Formulations:
Nebivolol 5mg, valsartan 80mg; tabs.
Indications for BYVALSON:
Initial therapy or if inadequately controlled on valsartan 80mg or nebivolol doses ≤10mg: 1 tab once daily.
Severe bradycardia. Heart block >1st-degree. Cardiogenic shock. Decompensated cardiac failure. Sick sinus syndrome (unless paced). Severe hepatic impairment (Child-Pugh >B). Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Hypotension: correct salt/volume depletion prior to initiation. Coronary artery disease, angina, post-MI, arrhythmias: avoid abrupt cessation (taper over 1–2 weeks). Worsening HF or fluid retention; consider diuretics and treat appropriately. Bronchospastic disease. Surgery. Diabetes. Hyperthyroidism. Peripheral vascular disease. Monitor renal function in renal artery stenosis, chronic kidney disease, severe CHF, or volume depletion. Risk of hyperkalemia; discontinue if necessary. Risk of anaphylactic reactions. Pheochromocytoma. Severe renal or moderate hepatic impairment: initial therapy not recommended. Severe hepatic impairment: not recommended. Neonates. Nursing mothers: not recommended.
See Contraindications. Avoid concomitant CYP2D6 inhibitors (eg, quinidine, propafenone, fluoxetine, paroxetine), other beta-blockers. If concomitant with clonidine, discontinue nebivolol for several days before tapering clonidine. Increased risk of bradycardia with concomitant digitalis glycosides; monitor. Concomitant anesthetics (eg, ether, cyclopropane, trichloroethylene), reserpine, guanethidine; monitor closely. β-blockers may mask hypoglycemia; caution with concomitant insulin or antihyperglycemics. Concomitant verapamil or diltiazem (monitor HR, BP), disopyramide (monitor HR, cardiac conduction). Concomitant K+ supplements, K+ sparing diuretics, K+-containing salt substitutes may cause hyperkalemia; monitor. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Dual inhibition of the renin-angiotensin system with ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely, in general, avoid combined use of RAS inhibitors. Concomitant aliskiren in renal impairment (GFR <60mL/min): not recommended. May increase lithium levels; monitor. May be potentiated by inhibitors of OATP1B1 (eg, rifampin, cyclosporine) or MRP2 (eg, ritonavir).
Beta-blocker + angiotensin II receptor blocker (ARB).
Hypotension, hyperkalemia, others; see full labeling.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma